India's Central Drugs Standard Control Organisation (CDSCO) approved Novo Nordisk's Wegovy (semaglutide injection 2.4 mg) on July 17, 2026 for the treatment of metabolic dysfunction-associated obesity in adults. Wegovy is a GLP-1 receptor agonist that suppresses appetite, reducing caloric intake and causing significant weight loss. It received FDA approval in the USA in 2021. India has over 13 crore adults classified as overweight or obese — making it a major public health concern. This is the most powerful obesity medication to receive India regulatory approval to date.
Science & Tech
CDSCO Approves Wegovy (Semaglutide 2.4 mg) in India for Obesity Treatment — Novo Nordisk; First GLP-1 for Weight Loss in India
Key Points
- India's Central Drugs Standard Control Organisation (CDSCO) approved Novo Nordisk's Wegovy (semaglutide injection 2.4 mg) on July 17, 2026 for the treatment of metabolic dysfunction-associated obesity in adults
- Wegovy is a GLP-1 receptor agonist that suppresses appetite, reducing caloric intake and causing significant weight loss
- It received FDA approval in the USA in 2021
- India has over 13 crore adults classified as overweight or obese — making it a major public health concern
- This is the most powerful obesity medication to receive India regulatory approval to date
📋
📎 Read original source ↗Exam Note
• CDSCO approves Wegovy (Semaglutide injection 2.4 mg): July 17, 2026; Novo Nordisk; obesity treatment • Wegovy: GLP-1 receptor agonist; reduces appetite; first FDA-approved in USA (2021) • CDSCO: Central Drugs Standard Control Organisation; under Ministry of Health and Family Welfare • India: 13 crore+ adults overweight/obese; Wegovy most powerful obesity drug approved in India
